Nicholas G Zaorsky1, Charles T Lee2, Eddie Zhang2, Scott W Keith3, Thomas J Galloway4. 1. Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, USA; Department of Radiation Oncology, Penn State Cancer Institute, Hershey, USA. Electronic address: nicholaszaorsky@gmail.com. 2. Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, USA. 3. Department of Pharmacology and Experimental Therapeutics, Division of Biostatistics, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, USA. 4. Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, USA. Electronic address: thomas.galloway@fccc.edu.
Abstract
PURPOSE: To characterize the cosmetic outcomes and local recurrence (LR) rates of various hypofractionated radiation therapy (RT) regimens for skin basal and squamous cell cancers (BCCs/SCCs). METHODS: A PICOS/PRISMA/MOOSE selection protocol was performed to identify 344 articles published between 1985-2016 evaluating patients with T1-2 N0 SCCs/BCCs treated with definitive RT. Biologically equivalent doses with α/β=3 (BED3s) were calculated. The primary endpoint was post-treatment cosmesis. Mixed effects regression models were used to estimate weighted linear relationships between BED3 and cosmetic outcomes. RESULTS: A total of 21 studies were identified detailing the treatment of 9729 skin BCC/SCC patients, across seven countries, with external beam RT (n=9255) or brachytherapy (n=474). Median follow-up was 36months (range: 12-77). Median dose was 45Gy/11 fractions (interquartile range: 37.5Gy/6-55Gy/18) at 4Gy/fraction (interquartile range: 2.5-6Gy); most hypofractionated 18.75Gy/1. There was a trend to decreased "good" cosmesis with higher total dose: -3.4% "good" cosmesis/10Gy BED3, p=0.01. Similarly, there was a trend to increased "fair" cosmesis with higher dose: +3.8% "fair" cosmesis/10Gy BED3,p=0.006. At a BED3 of 100Gy, the expected rate of "good" cosmesis is 79% (95% confidence interval: 70%, 88%). Hypofractionated schedules produced similar cosmesis to conventionally fractionated schedules, at the same BED3. Fewer than 8% of patients experienced "poor" cosmesis, independent of dose or fractionation regimen. CONCLUSION: Hypofractionated RT has favorable cosmesis for patients with skin BCCs/SCCs. We recommend clinicians consider these commonly-used regimens, which all have BED3 of ∼100Gy: 50Gy/15 fractions, 36.75Gy/7 fractions, or 35Gy/5 fractions, as they result in "good" cosmesis in 80% of patients.
PURPOSE: To characterize the cosmetic outcomes and local recurrence (LR) rates of various hypofractionated radiation therapy (RT) regimens for skin basal and squamous cell cancers (BCCs/SCCs). METHODS: A PICOS/PRISMA/MOOSE selection protocol was performed to identify 344 articles published between 1985-2016 evaluating patients with T1-2 N0 SCCs/BCCs treated with definitive RT. Biologically equivalent doses with α/β=3 (BED3s) were calculated. The primary endpoint was post-treatment cosmesis. Mixed effects regression models were used to estimate weighted linear relationships between BED3 and cosmetic outcomes. RESULTS: A total of 21 studies were identified detailing the treatment of 9729 skin BCC/SCCpatients, across seven countries, with external beam RT (n=9255) or brachytherapy (n=474). Median follow-up was 36months (range: 12-77). Median dose was 45Gy/11 fractions (interquartile range: 37.5Gy/6-55Gy/18) at 4Gy/fraction (interquartile range: 2.5-6Gy); most hypofractionated 18.75Gy/1. There was a trend to decreased "good" cosmesis with higher total dose: -3.4% "good" cosmesis/10Gy BED3, p=0.01. Similarly, there was a trend to increased "fair" cosmesis with higher dose: +3.8% "fair" cosmesis/10Gy BED3,p=0.006. At a BED3 of 100Gy, the expected rate of "good" cosmesis is 79% (95% confidence interval: 70%, 88%). Hypofractionated schedules produced similar cosmesis to conventionally fractionated schedules, at the same BED3. Fewer than 8% of patients experienced "poor" cosmesis, independent of dose or fractionation regimen. CONCLUSION: Hypofractionated RT has favorable cosmesis for patients with skin BCCs/SCCs. We recommend clinicians consider these commonly-used regimens, which all have BED3 of ∼100Gy: 50Gy/15 fractions, 36.75Gy/7 fractions, or 35Gy/5 fractions, as they result in "good" cosmesis in 80% of patients.
Authors: Timothy J Whelan; Jean-Philippe Pignol; Mark N Levine; Jim A Julian; Robert MacKenzie; Sameer Parpia; Wendy Shelley; Laval Grimard; Julie Bowen; Himu Lukka; Francisco Perera; Anthony Fyles; Ken Schneider; Sunil Gulavita; Carolyn Freeman Journal: N Engl J Med Date: 2010-02-11 Impact factor: 91.245
Authors: Nicholas G Zaorsky; Joshua D Palmer; Mark D Hurwitz; Scott W Keith; Adam P Dicker; Robert B Den Journal: Radiother Oncol Date: 2015-05-28 Impact factor: 6.280
Authors: Matthew E Johnson; Nicholas G Zaorsky; Jeffrey M Martin; Karen Ruth; Richard E Greenberg; Robert G Uzzo; Shelly B Hayes; Marc C Smaldone; Alexander Kutikov; Rosalia Viterbo; David Y T Chen; Mark A Hallman; Mark L Sobczak; Eric M Horwitz Journal: Can J Urol Date: 2016-12 Impact factor: 1.344
Authors: Chante Karimkhani; Robert P Dellavalle; Luc E Coffeng; Carsten Flohr; Roderick J Hay; Sinéad M Langan; Elaine O Nsoesie; Alize J Ferrari; Holly E Erskine; Jonathan I Silverberg; Theo Vos; Mohsen Naghavi Journal: JAMA Dermatol Date: 2017-05-01 Impact factor: 10.282
Authors: Vladimir Avkshtol; Yanqun Dong; Shelly B Hayes; Mark A Hallman; Robert A Price; Mark L Sobczak; Eric M Horwitz; Nicholas G Zaorsky Journal: Res Rep Urol Date: 2016-08-18
Authors: Mark S Nestor; Brian Berman; David Goldberg; Armand B Cognetta; Michael Gold; William Roth; Clay J Cockerell; Brad Glick Journal: J Clin Aesthet Dermatol Date: 2019-02-01
Authors: Sofian Benkhaled; Dirk Van Gestel; Carolina Gomes da Silveira Cauduro; Samuel Palumbo; Veronique Del Marmol; Antoine Desmet Journal: Front Med (Lausanne) Date: 2022-06-27